DFTX Stock Jumps Overnight As Investors Brace For Phase 3 Results From LSD-Based Anxiety Drug
Shares of Definium Therapeutics (DFTX) jumped 2% overnight late Sunday as investors awaited topline results from Panorama, the company’s second Phase 3 study of its LSD-based DT120 tablet in adults with generalized anxiety disorder.DFTX stock closed Friday’s session 3% higher at $38.89, capping its…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.